Review discusses pharmacogenomic biomarkers for pediatric B-ALL chemotherapy dosing

This narrative review focuses on the application of pharmacogenomic biomarkers and genotype-guided dose adjustment strategies within the context of pediatric B-cell acute lymphoblastic leukemia. The scope of the discussion centers on optimizing chemotherapy regimens to mitigate adverse effects while maintaining therapeutic efficacy. The authors highlight specific treatment-related toxicities, including 6-mercaptopurine-related toxicities, methotrexate-related gastrointestinal toxicity, and vincristine-induced neuropathy. These adverse events are noted as key considerations when evaluating the utility of biomarker-guided approaches.

The review synthesizes the potential benefits of integrating pharmacogenomic biomarkers into standard clinical protocols. The authors argue that such integration may represent a valuable strategy to avoid toxicity and improve overall cancer outcomes for this patient population. However, the text emphasizes that current evidence does not yet support widespread implementation without further validation. The authors explicitly state that further studies and innovative approaches are required to validate emerging biomarkers and facilitate their translation into routine clinical practice.

Practice relevance is framed cautiously, acknowledging the need for robust validation before routine adoption. The review does not report specific sample sizes, primary outcomes, or follow-up durations, as these details were not reported in the source material. Consequently, the conclusions remain qualitative, focusing on the potential utility of biomarkers rather than definitive clinical recommendations based on pooled data.